Bryostatin 1 in Treating Patients With Stage IV Breast Cancer
- Conditions
- Breast Cancer
- Registration Number
- NCT00003205
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with stage IV breast cancer.
- Detailed Description
OBJECTIVES:
* Determine the clinical response of patients with stage IV breast cancer to bryostatin 1.
* Determine the efficacy of this regimen in these patients.
* Estimate the pharmacokinetic parameters of bryostatin 1 when given as 24 hour infusion.
* Determine the ability of this regimen to regulate lymphocyte function in these patients.
* Determine the effect of this regimen on platelet function and protein kinase C activity in these patients.
OUTLINE: Patients receive bryostatin 1 IV over 24 hours. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
Patients are followed every 4-8 weeks for tumor response.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Colorado Cancer Center
🇺🇸Denver, Colorado, United States
University of Colorado Cancer Center🇺🇸Denver, Colorado, United States